Safety of bisphosphonates in the treatment of osteoporosis.
In this review 4 experts consider the major safety concerns relating to bisphosphonate therapy for osteoporosis. Specific topics covered are skeletal safety (particularly with respect to atypical fractures and delayed healing), gastrointestinal intolerance, hypocalcemia, acute-phase (i.e., postdose) reactions, chronic musculoskeletal pain, renal safety, and cardiovascular safety (specifically, atrial fibrillation).
Recker
Robert R
RR
School of Medicine, Creighton University, Omaha, Nebraska, USA.
Lewiecki
E Michael
EM
Miller
Paul D
PD
Reiffel
James
J
D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D002908:Chronic Disease; D004164:Diphosphonates / Q000009:adverse effects*; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D006996:Hypocalcemia / Q000139:chemically induced; D009140:Musculoskeletal Diseases / Q000139:chemically induced; D010024:Osteoporosis / Q000188:drug therapy*; D010146:Pain / Q000139:chemically induced
D050071:Bone Density Conservation Agents; D004164:Diphosphonates